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Deletion of KDM6A, a Histone Demethylase Interacting
with MLL2, in Three Patients with Kabuki Syndrome
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Sophie Claire Ghariani,3 Isabelle Maystadt,1 Bruno Dallapiccola,2 and Christine Verellen-Dumoulin1,4
Kabuki syndrome (KS) is a rare genetic disease that causes developmental delay and congenital anomalies. Since the identification of
MLL2 mutations as the primary cause of KS, such mutations have been identified in 56%–76% of affected individuals, suggesting
that there may be additional genes associated with KS. Here, we describe three KS individuals with de novo partial or complete deletions
of an X chromosome gene, KDM6A, that encodes a histone demethylase that interacts with MLL2. Although KDM6A escapes X inacti-
vation, we found a skewed X inactivation pattern, in which the deleted X chromosome was inactivated in the majority of the cells. This
study identifies KDM6Amutations as another cause of KS and highlights the growing role of histone methylases and histone demethy-
lases in multiple-congenital-anomaly and intellectual-disability syndromes.Kabuki syndrome (KS; MIM 147920) was first described in
1981 by Niikawa and Kuroki,1,2 and more than 400 cases
have been reported in the literature. The main clinical
characteristics are distinctive facial features, develop-
mental delay, mild to moderate intellectual disability,
post-natal growth retardation, and additional features
including skeletal anomalies, hypodontia, and persistent
fetal fingertip pads. Comparative genomic hybridization
(CGH) microarray analysis failed to detect a recurrent
anomaly in 72 KS individuals.3–8 Use of the exome-
sequencing strategy recently led to the identification of
MLL2 (MIM 602113) mutations as a major cause of KS.9
In five recently published series, mutations in MLL2 were
found in 56%–76% of KS patients.9–13
Because a significant proportion of patients do not have
a detectable MLL2 mutation, we postulated the existence
of additional genes associated with KS. In the quest for
a another KS-causing genetic mutation, ten genes interact-
ing with MLL2 were screened in 15 MLL2-mutation-nega-
tive KS individuals, and no pathogenic mutations were
identified.11 Another gene coding for an MLL2-interacting
protein, KDM6A (previously known as UTX; MIM 300128),
was screened in 22 MLL2-mutation-negative KS individ-
uals, and again, no causative mutations were detected.13
By using array CGH analysis (Agilent platform 244K), we
identified de novo Xp11.3 microdeletions in two Belgian
MLL2-mutation-negative KS girls (patients 1 and 2).
Because both deletions were de novo, they are probably
pathogenic. Both deletions included either a portion of
or all of KDM6A. Moreover, there were no KDM6A dele-
tions in a cohort of 411 normal controls in a previous
study.14 The deletion in patient 1 included KDM6A exons
21–29, which code for the terminal part of the catalytic
domain of KDM6A, and CXorf36, a gene recently impli-
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The AmericDUSP21 (MIM 300678), and FUNDC1 (Figure 1) were
removed completely. The functions of DUSP21 and
FUNDC1 remain unknown.
We then sequenced KDM6A by Sanger sequencing and
looked for intragenic deletions or duplications with a tar-
geted custom Agilent array CGH in a cohort of 22 MLL2-
mutation-negative KS individuals (8 females, 14 males).
In accordance with the ethical standards of the Institut
de Pathologie et de Ge´ne´tique ethics committee, parental
consent was obtained for DNA analysis of all the partici-
pants in this study and for the publication of photographs.
The CGH microarray data (supplemental data, available
online) discussed in this publication have been deposited
in the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO)16 and are acces-
sible under accession GSE32567 (see Accession Numbers
section).
No point mutations were detected, but we identified a de
novo intragenic deletion (exons 5–9) in one Italian, male
KS individual (patient 3). We also sequenced UTY (MIM
400009), the Y chromosome paralog of KDM6A (see
below), and looked for intragenic deletions or duplications
as stated above, but we did not detect any mutations.
Patients 1 and 3 had a typical KS phenotype, including
long palpebral fissures, lateral eversion of the lower eyelid,
and moderate to severe intellectual disability (Table 1 and
Figure 2). Although the facial features of patient 2 were
not as classical, she displayed many features of this
disorder, including lateral sparseness of the eyebrows,
long eyelashes, strabismus, long palpebral fissures, large
and prominent ears, persistent fetal fingertip pads, aortic
coarctation, areolar fullness in infancy, and hirsutism.
She presented with a mild developmental delay and had
a normal verbal intelligence quotient (IQ) score, a poor
performance IQ score, and hyperactive behavior (Table 1(Gosselies) 6041, Belgium; 2Department of Medical Genetics, Bambino Gesu`
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Figure 1. Region Xp11.3 Showing the Patients’ Deletions
Region Xp11.3 shows the deletions drawn from the UCSCGenome Browser (GRCh37/hg19) for patients 1, 2, and 3. The black full tracks
represent each patient’s deletion, and each patient’s number is above his or her respective track. The deletion in patient 1 spans 283.5 kb
from base 44,941,324 to base 45,224,829, patient 2’s deletion spans 815.7 kb from base 44,377,858 to base 45,193,629, and patient 3’s
deletion spans 45.4 kb from base 44,866,302 to base 44,912,718. The genes in the area are noted below the deletion tracks. CNVs in the
Database of Genomic Variants are shown on the bottom lines. There are no previous reports of KDM6A copy-number changes.and Figure 2). We noted that patients 1 and 2 had long
halluces (Figure 3).
Thus, the KDM6A deletions in these three patients are
associated with a broad phenotypic spectrum ranging
from typical KS individuals (patients 1 and 3) to a milder
clinical presentation (patient 2). This clinical variability
is also a feature of patients with MLL2 mutations.13
However, the possible effects of CXorf36 deletion in
patient 1 and of CXorf36, DUSP21, and FUNDC1 deletion
in patient 2 on their respective phenotypes should also
be considered.
KDM6A (29 exons) is one of the X chromosomal genes
that largely escapes X inactivation.17 It encodes a 1,401
residue protein that contains two functional domains.
The catalytic domain is a histone demethylase that
specifically catalyzes demethylation of mono-, di-, and
trimethylated lysine 27 on histone H3 (H3K27).18,19 This
demethylation mediates tissue-specific expression of
various genes and is mostly involved in developmental
processes and the cell cycle.19–22 Interestingly, KDM6A
and MLL2 act together in the epigenetic control of tran-
scriptionally active chromatin by counteracting Poly-
comb-group (PcG) proteins.22 The other functional
domain of KDM6A plays a role in chromatin remodeling
by interacting with the switch/sucrose nonfermentable
(SWI/SNF) remodeling complex that contains the tran-
scription activator Brg1.23
Like MLL2, KDM6A plays a role in embryogenesis and
development. Homozygous dUTX (Drosophila KDM6A
ortholog) Drosophila mutants manifest rough eyes, dys-
morphic wings, and modification of the sex combs.21
This phenotype resembles the trithorax phenotype,
further supporting the notion that KDM6A counteracts
PcG repression.21 Moreover, UTX-1 (C. elegans KDM6A
ortholog) might affect developmental fate decisions in
C. elegans vulval precursor cells via the transcription regu-120 The American Journal of Human Genetics 90, 119–124, January 1lation of genes that encode the retinoblastoma (RB)
protein complex, which has been conserved from worms
to humans.20 Kdm6a1 is also important in the expression
of posterior HOX genes in Zebrafish.19 In addition,
KDM6A, together with MLL2, plays a major role in the
regulation of muscle-specific genes during embryogen-
esis.22,24 Finally, members of another important develop-
mental gene family (T-box genes, which act in the meso-
derm in the formation of the heart and vertebrae) recruit
KDM6A to activate their target genes, again emphasizing
the role of KDM6A in developmental processes.23 Interest-
ingly, most of the pathogenic mutations for reported T-box
genes in human diseases are located in the T-box domain
that interacts with KDM6A.23
KDM6A escapes X inactivation,17 but it has been sug-
gested that in mice, Kdm6a expression from the inactive
X chromosome is significantly lower than that from the
active X chromosome.25 Kdm6a expression is higher in
the adult brain, the adult liver, and specific developing
brain regions in females than in males.25 UTY is the pa-
ralog of KDM6A on the Y chromosome.17 UTY has 84%
amino acid sequence similarity with KDM6A and might
compensate for the increased expression of KDM6A in
females, despite the fact that demethylase activity has yet
to be demonstrated for this KDM6A paralog.14,25
It is not surprising to find another gene associated with
KS on the X chromosome because there have been reports
of KS-like patients with small ring X (r[X]) chromo-
somes.26–34 In addition, there is a clear overlap between
the congenital heart defects prevalent in male KS patients
(aortic coarctation and other left-sided obstructions) and
those found in patients with monosomy X and r(X) chro-
mosomes.28,35 Small r(X) chromosomes typically lead to
Turner syndrome through the complete inactivation of
the r(X). However, it is unclear why some individuals
develop a KS-like phenotype. Incomplete X chromosome3, 2012
Table 1. Clinical Features of Patients
Patient 1 Patient 2 Patient 3
General Characteristics
Gender female female male
Maternal age at birth (yr) 36 36 25
Paternal age at birth (yr) 39 29 27
Age at examination (yr) 13 10 2
Weight <P3 - þ þ
Length <P3 þ þ þ
OFC <P3 þ þ þ
NN hypoglycemia þ - þ
Areolar fullness in infancy þ þ þ
Persistent finger pads þ þ þ
Brachydactyly - - þ
Hyperlaxity þ þ þ
Hirsutism þ þ þ
Feeding difficulties in
infancy
þ - þ
CHD ASD AoC -
Renal malformation ND - -
Cancer - - -
Developmental delay severe mild moderate
IQ Tot: 41a V: 87, P:74b Tot: 54c
Hypotonia þ - þ
Behavior trouble þ þ -
Facial Characteristics
Arched eyebrow þ - þ
Lateral sparse of the
eyebrow
- þ þ
Long palpebral fissure þ þ þ
Long eyelashes þ þ þ
Eversion of lateral third
of the inferior eyelid
þ - þ
Broad tip þ þ þ
Depressed tip þ - þ
Short columella þ - þ
Strabismus þ þ -
High arched palate þ - þ
Neonatal teeth - - -
Dental malocclusion þ - þ
Ear Characteristics
Prominent - þ þ
Cupped - - þ
Large auricle þ þ -
Hearing loss - - -
The Americinactivation and the subsequent expression of usually
repressed genes has been suggested as an explanation for
the KS phenotype in some r(X) patients.32–34 KDM6A was
deleted in the three patients who had both a KS-like
phenotype and a r(X) in which the breakpoints had been
mapped; this finding is consistent with the hypothesis
that KDM6A deletion plays an important role in the KS-
like phenotype observed in some patients with
a r(X).30,32,34 We were unable to prove haploinsufficiency
for KDM6A in patients 1 and 2 because KDM6A expression
was very low in peripheral blood lymphocytes (data not
shown). Nevertheless, studies have shown that two copies
of Kdm6a are necessary for normal expression in female
mouse embryos and adult mice,25 suggesting that haploin-
sufficiencymight be the pathogenic mechanism. However,
this explanation would not account for the fact that 45,X
and other r(X) patients with a KDM6A deletion do not all
develop the Kabuki phenotype.
Inpatients 1and2, themolecularX inactivation ratios are
strongly skewed and are 89:11 and 97:3, respectively. The X
inactivation profile was determined via PCR amplification
of the CAG repeat in exon 1 of the androgen-receptor
gene before and after DNA digestion with HpaII and CfoI.
To determine whether the deleted copy of KDM6A was
located on the active or inactive X chromosome, we per-
formed fluorescence in situ hybridization (FISH) analysis
with a KDM6A probe on the X chromosomes that had
been differentially labeled by the incorporation of
5-bromo-20-deoxyuridine (5-BrdU). The results showed
that the deleted copy ofKDM6Awas located on the inactive
X chromosome in all of the 70 mitoses analyzed in both
patients (Figure 4). The fact thatKDM6A escapesX-inactiva-
tion17 suggests that the phytohemagglutinin (PHA)-stimu-
lated lymphocytes that have a deleted copy of KDM6A on
the inactive X chromosome have a survival advantage
over cell lines that have a deleted copy of KDM6A on the
active X chromosome. This suggestion is in line with the
hypothesis that although KDM6A escapes X inactivation,
its expression is lower from the inactive X chromosome
than from the active X chromosome.25
The role of UTY is largely unknown, and it has no
in vitro demethylase activity. The finding of amale KS indi-
vidual (patient 3) with an intragenic deletion of KDM6A
and with clinical severity similar to that of patient 1
suggests that UTY could partially compensate for the loss
of KDM6A in male individuals, as previously suggested in
the literature.25
As for MLL2, somatic homozygous and hemizygous
mutations in KDM6A have been identified in variousAbbreviations are as follows: OFC, occipitofrontal circumference; NN,
neonatal; CHD, congenital heart disease; ASD, atrial septal defect; AoC, aortic
coarctation; ND, not determined; Tot, total; V, verbal; and P, performance.
a IQ examined at 12 years of agewith theWechsler Intelligence Scale (WISC III).
b IQ examined at 5 years of age with theWechsler Intelligence Scale (WPPSI-R).
c IQ examined at 14 months of age with the Griffith Mental Developmental
Scale.
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Figure 2. Facial Appearance in Affected Individuals
(A) Patient 1.
(B) Patient 2.
(C) Patient 3.
Note the long palpebral fissures in patients 1 and 2 and the arched
eyebrows in patients 1 (mild) and 3.
Figure 4. Image of FISH Study on X Chromosomes Differentially
Labeled with 5-BrdU
An image of a FISH study shows X chromosomes differentially
labeled by the incorporation of 5-BrdU. The inactive X chromo-
some (in the white circle) appears brighter than the active X chro-
mosome. Xqter subtelomeric probes hybridize to both X chromo-
somes (blue arrows). The KDM6A signal (white arrow) is absent
from the inactive X chromosome and is present on the active
X chromosome. For this experiment, peripheral blood lympho-
cytes from patients 1 and 2 were stimulated with phytohemagglu-
tinin and were cultured for 72 hr. In order to identify the
late-replicating inactive X chromosome, we treated the cells with
5-BrdU (30 mg/ml) 5 hr prior to harvesting. Colcemid was then
added to a concentration of 0.2 mg/ml, and 1 hr later, metaphase
preparations were produced via standard procedures involving
swelling in 75 mM KCl and fixing in 3:1 methanol/acetic acid.
We performed FISH analysis by simultaneously using a subtelo-
meric Xqter probe labeled with SpectrumOrange (Vysis) to indi-
cate the X chromosomes (blue arrow) and RP11-435K1 labeled
with SpectrumOrange (AmpliTech) to distinguish between the
deleted and nondeleted X chromosomes (white arrow). To facili-
tate the detection of incorporated 5-BrdU, we denatured cellular
DNA in 2N HCl for 30 min at 37C. 5-BrdU was then labeled
with a 5-BrdU-specific monoclonal antibody conjugated to fluo-
rescein (Roche) (1 mg/ml). Finally, we counterstained the DNA by
applying an antifade solution containing 0.1 mg/ml DAPI.cancer types (multiple myeloma, esophageal squamous
cell carcinoma, renal cell carcinoma, myeloid leukemia,
breast cancer, colorectal cancer, and glioblastoma), sug-
gesting that KDM6A is a tumor-suppressing gene.14 Never-
theless, cancer is not a key feature of KS, given that this
complication has been reported in only seven KS
patients36,37 (acute lymphoblastic leukemia, Burkitt
lymphoma, fibromyxoid sarcoma, synovial sarcoma, and
hepatoblastoma were reported once, and neuroblastoma
was reported in two KS individuals).35,36 If loss of both
alleles is sufficient enough to cause cancer, one would
expect cancer to occur more frequently in KS, such as in
retinoblastoma (MIM 180200) or Wilms tumor (MIM
194070). This suggests either that loss of the second allele
in MLL2, KDM6A, or UTY is necessary but not sufficient
enough for cancer development or that this complication
is underrecognized, demonstrating the importance of
natural-history studies in rare syndromes.37
The following histone methylases and histone demethy-
lases have been implicated in other multiple-anomaly
syndromes: EHMT1 (MIM 607001; Kleefstra syndrome
[MIM 610253]), SETBP1 (MIM 611060; Schinzel-Giedion
syndrome [MIM 269150]), JARID1C (MIM 314690; Claes-
Jensen-type, X-linked mental-retardation syndrome [MIM
300534]), PHF8 (MIM 300560; Siderius-type, X-linked
mental-retardation syndrome [MIM 300263]), and MLL2Figure 3. Appearance of Feet in Affected Individuals
(A) Patient 1.
(B) Patient 2.
Note the long halluces in both patients.
122 The American Journal of Human Genetics 90, 119–124, January 1in KS. The identification of KDM6A pathogenic mutations
in KS patients expands the role of histone-modification
factors in intellectual disability and congenital malforma-
tion.
In conclusion, we report KDM6Amutations as a cause of
KS in one male and two females. Our findings confirm
both KS genetic heterogeneity and a locus on the X chro-
mosome, as has been suggested previously. Because some
KS patients were negative for MLL2, KDM6A, and UTY
sequencing and did not show deletions or duplications
during screening, it is likely that other KS-associated genes
remain to be discovered.Supplemental Data
Supplemental Data include a PDF with the CGH procedure and
a description of the .txt files and 11 .txt files with all the CGH mi-
croarray data.3, 2012
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